A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Cited by (1,001)

Items 301–400 of 1,001

1. Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals
   Douglas R Galasko, Neill R. Graff‐Radford, Susanne J. May, Suzanne B. Hendrix, Barbara A. Cottrell, Sarah A. Sagi, GARY G. MATHER, Mark A Laughlin, Kenton H. Zavitz, Edward A. Swabb et al. · 2007 · Alzheimer Disease & Associated Disorders
2. Sequence Determinants of Enhanced Amyloidogenicity of Alzheimer Aβ42 Peptide Relative to Aβ40
   Woojin Kim, Michael H. Hecht · 2005 · Journal of Biological Chemistry
3. Does NSAID use modify cognitive trajectories in the elderly?
   Kathleen M. Hayden, Peter P. Zandi, Ara S. Khachaturian, Christine A. Szekely, Majid Fotuhi, Maria C. Norton, JoAnn T. Tschanz, Carl F. Pieper, Cheryl Mary Corcoran, Constantine George Lyketsos et al. · 2007 · Neurology
4. Regulation of Notch Signaling by Dynamic Changes in the Precision of S3 Cleavage of Notch-1
   Shinji Tagami, Masayasu Okochi, Kanta Yanagida, Akiko Ikuta, Akio Fukumori, Naohiko Matsumoto, Yoshiko Ishizuka‐Katsura, Taisuke Nakayama, Naohiro Itoh, Jingwei Jiang et al. · 2007 · Molecular and Cellular Biology
5. No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
   Szekely, C. A., Green, R. C., Breitner, J.C.S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H. et al. · 2008 · Neurology
6. Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
   Golde, Todd E. · 2022 · Neurotherapeutics
7. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease
   Nicholas H. Varvel, Kiran Bhaskar, Maria Z. Kounnas, Steven L. Wagner, Yan Yang, Bruce T. Lamb, Karl Herrup · 2009 · Journal of Clinical Investigation
8. Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
   Zimmer, Eduardo Rigon, Leuzy, Antoine, Benedet, Andréa Lessa, Breitner, John, Gauthier, Serge, Rosa-Neto, Pedro · 2014 · Journal of Neuroinflammation
9. Modulation of inflammation in transgenic models of Alzheimer’s disease
   Amy M. Birch, Loukia Katsouri, Magdalena Sastre · 2014 · Journal of Neuroinflammation
10. Current therapeutic targets for the treatment of Alzheimer’s disease
    Joshua D. Grill, Jeffrey L. Cummings · 2010 · Expert Review of Neurotherapeutics
11. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons
    Jaya Padmanabhan, Monique M. Levy, Dennis W. Dickson, Huntington Potter · 2006 · Brain
12. Antinociceptive Action of Nitrous Oxide Is Mediated by Stimulation of Noradrenergic Neurons in the Brainstem and Activation of α2BAdrenoceptors
    Shigehito Sawamura, Wade S. Kingery, M. Frances Davies, Geeta S. Agashe, J. David Clark, Brian K. Kobilka, Toshizaku Hashimoto, Mervyn Maze · 2000 · Journal of Neuroscience
13. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders
    Takekazu Kubo · 2008 · Therapeutics and Clinical Risk Management
14. Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond
    De Strooper, Bart, Chávez Gutiérrez, Lucía · 2015 · Annual Review of Pharmacology and Toxicology
15. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?
    Niki S.M. Schoonenboom, Cees Mulder, Gerard J. van Kamp, Sangita P. Mehta, Philip Scheltens, Marinus A. Blankenstein, Pankaj D Mehta · 2005 · Annals of Neurology
16. Therapeutic Strategies for Alzheimer’s Disease
    Donna M. Barten, Charles F. Albright · 2008 · Molecular Neurobiology
17. Intramembrane Proteolysis
    Michael S. Wolfe · 2009 · Chemical Reviews
18. Effects of Membrane Lipids on the Activity and Processivity of Purified γ-Secretase
    Oliver Wendell Holmes, Swetha Paturi, Wenjuan Ye, Michael S. Wolfe, Dennis J. Selkoe · 2012 · Biochemistry
19. Inhomogeneous distribution of Iba‐1 characterizes microglial pathology in Alzheimer's disease
    Jasmin Tischer, Martin Krueger, Wolf C. Mueller, Ori Staszewski, Marco Prinz, Wolfgang J. Streit, Ingo Bechmann · 2016 · Glia
20. Impact of amyloid imaging on drug development in Alzheimer's disease
    Chester A. Mathis, Brian J. Lopresti, William Edward Klunk · 2007 · Nuclear Medicine and Biology
21. Alzheimer's disease: β‐Amyloid protein and tau
    Maho Morishima‐Kawashima, Yasuo Ihara · 2002 · Journal of Neuroscience Research
22. Novel therapeutic strategies for the treatment of protein-misfolding diseases
    Jean‐Christophe Rochet · 2007 · Expert Reviews in Molecular Medicine
23. Disease modifying therapy for AD?1
    Golde, Todd E. · 2006 · Journal of Neurochemistry
24. Sleep and Alzheimer's disease: A pivotal role for the suprachiasmatic nucleus
    Jan Van Erum, Debby Van Dam, Peter Paul De Deyn · 2017 · Sleep Medicine Reviews
25. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
    Zoe Arvanitakis, Francine Grodstein, Julia L. Bienias, Julie A. Schneider, R. S. Wilson, Jeremiah F. Kelly, Denis A. Evans, David Alan Bennett · 2008 · Neurology
26. Pharmacotherapy for Alzheimer's disease: progress and prospects
    Alan M. Palmer · 2002 · Trends in Pharmacological Sciences
27. Neuroinflammation: a potential therapeutic target
    Craft, Jeffrey M, Watterson, D Martin, Van Eldik, Linda J · 2005 · Expert Opinion on Therapeutic Targets
28. Structure and Function of the γ-Secretase Complex
    Michael S. Wolfe · 2019 · Biochemistry
29. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease
    Brandy L. Wilkinson, Paige E. Cramer, Nicholas H. Varvel, Erin G. Reed-Geaghan, Qingguang Jiang, Alison Szabo, Karl Herrup, Bruce T. Lamb, Gary E. Landreth · 2010 · Neurobiology of Aging
30. Alzhemed: A Potential Treatment for Alzheimers Disease
    Paul S. S Aisen, Serge G. Gauthier, Bruno J. Vellas, Richard Briand, Daniel Saumier, Julie Laurin, D. Garceau · 2007 · Current Alzheimer Research
31. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease
    Axel Petzold, R. Jenkins, Hilary Watt, A.J.E Green, E J Thompson, Geoffrey Keir, Nick C. Fox, Martin N. Rossor · 2003 · Neuroscience Letters
32. Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced Aβ Phagocytosis yet Lack Aβ-Activated Neurotoxicity
    Feng‐Shiun Shie, RICHARD M. BREYER, Thomas Jude Montine · 2005 · American Journal Of Pathology
33. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
    Julie Dunys, Audrey Valverde, Frédéric Checler · 2018 · Journal of Biological Chemistry
34. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology
    Maria Teresa Ferretti, Simon Allard, Vanessa Partridge, Adriana Ducatenzeiler, A. Claudio Cuello · 2012 · Journal of Neuroinflammation
35. When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer's disease
    Avila-Muñoz, Evangelina, Arias, Clorinda · 2014 · Ageing Research Reviews
36. The therapeutics of Alzheimer's disease: Where we stand and where we are heading
    Dennis J. Selkoe · 2013 · Annals of Neurology
37. Progress in Alzheimer’s disease
    Daniela Galimberti, Elio Angelo Scarpini · 2011 · Journal of Neurology
38. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice
    Stephanos Kyrkanides, Ross H. Tallents, Jen‐nie H. Miller, Mallory E. Olschowka, Renee E. Johnson, Meixiang Yang, John A. Olschowka, Sabine M. Brouxhon, M. Kerry O’Banion · 2011 · Journal of Neuroinflammation
39. Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease
    Thomas Jude Montine, Jason D. Morrow · 2005 · American Journal Of Pathology
40. 2-dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease
    Eric D. Agdeppa · 2003 · Molecular Imaging and Biology
41. Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1
    Yu Ohki, Takuya Higo, Kengo Uemura, Naoaki Shimada, Satoko Osawa, Oksana Berezovska, Satoshi Yokoshima, Tohru Fukuyama, Taisuke Tomita, Takeshi Iwatsubo · 2011 · The EMBO Journal
42. Rho GTPases as therapeutic targets in Alzheimer’s disease
    Byron J. Aguilar, Yi Zhu, Qun Lu · 2017 · Alzheimer s Research & Therapy
43. Results of a follow‐up study to the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT)
    The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group · 2013 · Alzheimer s & Dementia
44. Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid1-42Secretion
    Ilaria Peretto, Stefano Redaelli, Carlo Parini, Michele Zandi, Luca F. Raveglia, Giulio Massimo Dondio, Laura Fontanella, Paola Misiano, Chiara Bigogno, Andrea Rizzi et al. · 2005 · Journal of Medicinal Chemistry
45. Presenilin-1 L166P Mutant Human Pluripotent Stem Cell–Derived Neurons Exhibit Partial Loss of γ-Secretase Activity in Endogenous Amyloid-β Generation
    Philipp Koch, Irfan Y. Tamboli, Jérôme Mertens, Patrick Wunderlich, Julia Ladewig, Kathrin Stüber, Hermann Esselmann, Jens Wiltfang, Oliver Brüstle, Jochen Walter · 2012 · American Journal Of Pathology
46. Substituted 2-Thioxoimidazolidin-4-ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates
    Giulio G. Muccioli, Nicola Fazio, Gerhard K. E. Scriba, Wolfgang Poppitz, Fabio Cannata, Jacques Henri Poupaert, Johan Wouters, Didier M. Lambert · 2005 · Journal of Medicinal Chemistry
47. Presenilin-dependent regulated intramembrane proteolysis and γ-secretase activity
    Justin V. McCarthy, Ciara Twomey, Piotr Wujek · 2009 · Cellular and Molecular Life Sciences
48. Randomized, controlled, cross-over clinical trial comparing intravenous midazolam sedation with nitrous oxide sedation in children undergoing dental extractions
    Kathy Wilson, N M Girdler, Richard R. Welbury · 2003 · British Journal of Anaesthesia
49. Role of the Immune System in the Pathogenesis, Prevention and Treatment of Alzheimer??s Disease
    Blasko, Imrich, Grubeck-Loebenstein, Beatrix · 2003 · Drugs & Aging
50. Rhodium‐Catalyzed Hydrocarboxylation of Olefins with Carbon Dioxide
    Shingo Kawashima, Kohsuke Aikawa, Köichi Mikami · 2016 · European Journal of Organic Chemistry
51. Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity
    Weiping Qin, Lap Ho, Patrick N. Pompl, Yuanzhen Peng, Zhong Zhao, Zhongmin Xiang, Nikolaos K. R K Robakis, Junichi Shioi, Jason Suh, Giulio Maria Pasinetti · 2003 · Journal of Biological Chemistry
52. γ-Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin
    Nikolay Pozdnyakov, Heather E. Murrey, Christina J. Crump, Martin Pettersson, T. Eric Ballard, Christopher W. am Ende, Kwangwook Ahn, Yue‐Ming Li, Kelly R. Bales, Douglas S. Johnson · 2013 · Journal of Biological Chemistry
53. Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
    Vincenza Frisardi, Vincenzo Solfrizzi, Bruno Pietro Imbimbo, Cristiano A. Capurso, Alessia D’Introno, Anna Maria Colacicco, Gianluigi Vendemiale, Davide Seripa, Alberto Pilotto, Cristiano A. Capurso et al. · 2010 · Current Alzheimer Research
54. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer’s disease model mice
    Nathaniel S. Woodling, Damien Colas, Qian Wang, Paras Singh Minhas, Maharshi Panchal, Xibin Liang, Siddhita D. Mhatre, Holden D. Brown, Novie Ko, Irene A. Zagol-Ikapitte et al. · 2016 · Brain
55. The effect of insomnia on development of Alzheimer’s disease
    Shaghayegh Sadeghmousavi, Mahsa Eskian, Farzaneh Rahmani, Nima Rezaei · 2020 · Journal of Neuroinflammation
56. In vitro Models of the Blood–Brain Barrier: Tools in Translational Medicine
    Alberto R. Williams-Medina, Michael C. Deblock, Damir Janigro · 2021 · Frontiers in Medical Technology
57. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease
    Bruno Pietro Imbimbo · 2009 · Expert Opinion on Investigational Drugs
58. Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease
    Wilcock, Donna M. · 2012 · Current Gerontology and Geriatrics Research
59. Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization
    Luise Richter, Lisa Marie Munter, Julia Neß, Peter Werner Hildebrand, Muralidhar Dasari, Stephanie Unterreitmeier, Bruno Bulic, Michael Beyermann, Ronald Gust, Bernd Reif et al. · 2010 · Proceedings of the National Academy of Sciences
60. Declining prevalence of dementia in the U.S. elderly population.
    K. Manton, Xuelan Gu, Svetlana V. Ukraintseva · 2005 · PubMed
61. PPARγ as a therapeutic target in central nervous system diseases
    Sriram Surendra Sundararajan, Qingguang Jiang, Michael Thomas Heneka, Gary E. Landreth · 2006 · Neurochemistry International
62. Inhibition of ??-Secretase as a Therapeutic Intervention for Alzheimer???s Disease
    Genevieve M. Evin, M. Fleur Sernee, Colin Louis Masters · 2006 · CNS Drugs
63. IPAF inflammasome is involved in interleukin-1β production from astrocytes, induced by palmitate; implications for Alzheimer's Disease
    Li Liu, Christina Chan · 2013 · Neurobiology of Aging
64. The Role of Adenosine in Alzheimers Disease
    Anisur Rahman · 2009 · Current Neuropharmacology
65. Low dose aspirin and cognitive function in the women's health study cognitive cohort
    Kang, Jae Hee, Cook, Nancy, Manson, JoAnn, Buring, Julie E, Grodstein, Francine · 2007 · BMJ
66. APP Intracellular Domain Impairs Adult Neurogenesis in Transgenic Mice by Inducing Neuroinflammation
    Kaushik Ghosal, Andrea M. Stathopoulos, Sanjay W. Pimplikar · 2010 · PLoS ONE
67. The Role of Adams in Notch Signaling
    Arjan J. Groot, Marc Vooijs · 2012 · Advances in experimental medicine and biology
68. The Development of Anti-Amyloid Therapy for Alzheimer???s Disease
    Paul S. S. Aisen · 2005 · CNS Drugs
69. Alpha7 nicotinic acetylcholine receptor: A link between inflammation and neurodegeneration
    Concepcion Conejero‐Goldberg, Peter Davies, Luis Ulloa · 2007 · Neuroscience & Biobehavioral Reviews
70. Oxidative stress in Alzheimer’s Disease: Implications for Prevention and Therapy
    Christian Behl · 2006 · Springer eBooks
71. Secretion of the Notch-1 Aβ-like Peptide during Notch Signaling
    Masayasu Okochi, Akio Fukumori, Jingwei Jiang, Naohiro Itoh, Ryo Kimura, Harald Steiner, Christian Haass, Shinji Tagami, Masatoshi Takeda · 2006 · Journal of Biological Chemistry
72. Synthesis and Assignment of Absolute Configuration of (−)-Oleocanthal: A Potent, Naturally Occurring Non-steroidal Anti-inflammatory and Anti-oxidant Agent Derived from Extra Virgin Olive Oils
    Amos B. Smith, Qiang Han, Paul A. S. Breslin, Gary K. Beauchamp · 2005 · Organic Letters
73. γ-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site
    Patrick C. Fraering, Wenjuan Ye, Matthew J. LaVoie, Beth L. Ostaszewski, Dennis J. Selkoe, Michael S. Wolfe · 2005 · Journal of Biological Chemistry
74. Alzheimer's disease and the amyloid cascade hypothesis: ten years on
    Bernd Sommer · 2002 · Current Opinion in Pharmacology
75. Modulation of β‐amyloid metabolism by non‐steroidal anti‐inflammatory drugs in neuronal cell cultures
    Laura Gasparini, Laura Rusconi, Huaxi Xu, Piero Del Soldato, Ennio Ongini · 2003 · Journal of Neurochemistry
76. Regulation of β‐site APP‐cleaving enzyme 1 gene expression and its role in Alzheimer’s Disease
    Xiulian Sun, Kelley Bromley‐Brits, Weihong Song · 2011 · Journal of Neurochemistry
77. Inflammation in transgenic mouse models of neurodegenerative disorders
    Schwab, Claudia, Klegeris, Andis, McGeer, Patrick. L. · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
78. Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum
    Dejan Milatović, Snjezana Zaja‐Milatovic, Kathleen S. Montine, Philip J. Horner, Thomas Jude Montine · 2003 · Journal of Neurochemistry
79. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
    Bruno Pietro Imbimbo, Francesco Panza, Vincenza Frisardi, Vincenzo Solfrizzi, Grazia D’Onofrio, Giancarlo Logroscino, Davide Seripa, Alberto Pilotto · 2011 · Expert Opinion on Investigational Drugs
80. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid
    Donna M. Wilcock, Paul T. Jantzen, Qi Li, David Morgan, Marcia N. Gordon · 2006 · Neuroscience
81. Structure and function of γ-secretase
    Alexandra Tolia, Bart De Strooper · 2008 · Seminars in Cell and Developmental Biology
82. Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman
    Dennis J. Selkoe · 2003 · Neurochemical Research
83. Interleukins, Inflammation, and Mechanisms of Alzheimer's Disease
    Weisman, David, Hakimian, Edwin, Ho, Gilbert J. · 2006 · Vitamins & Hormones
84. Microglia in Alzheimer's Disease: It's All About Context
    Weitz, Tara M., Town, Terrence · 2012 · International Journal of Alzheimer's Disease
85. BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity
    Christina J. Crump, Suita V. Castro, Feng Wang, Nikolay Pozdnyakov, T. Eric Ballard, Sangram S. Sisodia, Kelly R. Bales, Douglas S. Johnson, Yue‐Ming Li · 2012 · Biochemistry
86. Ibuprofen Suppresses Interleukin-1β Induction of Pro-Amyloidogenic α1-Antichymotrypsin to Ameliorate β-Amyloid (Aβ) Pathology in Alzheimer's Models
    Takashi Morihara, Bruce Teter, Fusheng Yang, Giselle P. Lim, Sally G. Boudinot, F. Douglas Boudinot, Sally Ann Frautschy, Greg M. Cole · 2005 · Neuropsychopharmacology
87. Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897
    Jeffery J. Anderson, Greg Holtz, Patricia P. Baskin, Mary Turner, Blake A. Rowe, Bowei Wang, Maria Z. Kounnas, Bruce T. Lamb, Donna M. Barten, Kevin M. Felsenstein et al. · 2005 · Biochemical Pharmacology
88. Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad‐spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain‐derived neurotrophic factor
    Kendra N. Shaw, Seán Commins, Shane M. O’Mara · 2003 · European Journal of Neuroscience
89. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
    Lleo, A., Galea, E., Sastre, M. · 2007 · Cellular and Molecular Life Sciences
90. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease
    Ju Shi, Qian Wang, Jenny U. Johansson, Xibin Liang, Nathaniel S. Woodling, Prachi G. Priyam, Taylor Loui, Milton J. Merchant, RICHARD M. BREYER, Thomas Jude Montine et al. · 2012 · Annals of Neurology
91. EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimerʼns disease
    Tai, Leon M., Balu, Deebika, Avila-Munoz, Evangelina, Abdullah, Laila, Thomas, Riya, Collins, Nicole, Valencia-Olvera, Ana Carolina, LaDu, Mary Jo · 2017 · Journal of Lipid Research
92. High-throughput electronic biology: mining information for drug discovery
    William Loging, Lee Harland, Bryn Williams–Jones · 2007 · Nature Reviews Drug Discovery
93. Alzheimer’s disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production
    Mitko I. Dimitrov, Jean‐René Alattia, Thomas Lemmin, Rajwinder Lehal, Andrzej Fligier, Jemila Houacine, Ishrut Hussain, Freddy Radtke, Matteo Dal Peraro, Dirk Beher et al. · 2013 · Nature Communications
94. Disease-Modifying Therapies in Alzheimer???s Disease
    Michael H ll, Thomas Berger, Michael Thomas Heneka · 2006 · Drugs
95. The cell cycle as a therapeutic target for Alzheimer's disease
    Neve, Rachael L., McPhie, Donna L. · 2006 · Pharmacology & Therapeutics
96. A GPCR/secretase complex regulates β- and γ-secretase specificity for Aβ production and contributes to AD pathogenesis
    Lin Teng, Jian Zhao, Feifei Wang, Lan Ma, Gang Pei · 2010 · Cell Research
97. Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system
    Sandra J. Hewett, Stanley Charles Bell, James A. Hewett · 2006 · Pharmacology & Therapeutics
98. Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats
    Michael H. Mesches, Carmelina Gemma, Lone Veng, Chrissy A. Allgeier, David Alan Young, Michael D Browning, Paula C. Bickford · 2003 · Neurobiology of Aging
99. A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
    Brian Stephen Appleby, Dimitrios A. Nacopoulos, Nicholas J. Milano, Kate Zhong, Jeffrey L. Cummings · 2013 · Dementia and Geriatric Cognitive Disorders
100. Prevention of CIND by physical activity: Different impact on VCI-ND compared with MCI
     Laura Elizabeth Middleton, Susan Kirkland, Kenneth J. Rockwood · 2008 · Journal of the Neurological Sciences